DARA inhibits the adhesion of myeloma cells to stroma, inhibits the formation of nanotubes that transfer mitochondria from stromal cells to myeloma cells, depletes CD38+ regulatory cells of the T-, B- and M-phenotype and stimulates cytotoxic T-cells directly leading to the expansion and activation of cytotoxic T cells [6,7,8,9]. This evidence concerns the gene CD38 and plasma cell myeloma.